Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...

Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that ...

Eli Lilly (LLY) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

In 2022, over 1 billion people were affected by obesity, driving innovation in therapeutic advancements. Emerging treatments focus on appetite contro ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18 ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 trillion stock and the first healthcare company to do so. Trading at $852 per ...

INDIANAPOLIS — Indianapolis-based pharmaceutical giant Eli Lilly and Company will invest up to $250 million as part of an expanded partnership with Purdue University announced Friday, May 9. The ...

INDIANAPOLIS, May 8, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) ... The company anticipates continued growth in these areas, along with further pipeline advancement.